Register to receive a free Minimally Invasive Spinal Implants Market Report Suite for US 2017-2023 synopsis and brochure
Minimally invasive surgery (MIS) technologies continue to be one of the most innovative areas of the global spine device industry, with many factors driving growth.
One of the catalysts of this market movement is the participation of key market players, and their dedication to development, application, and education. While many external drivers and limiters also affect this market, the activities of leading competitors with a strong MIS focus, like NuVasive, are a great example of this drive for development in not only products, but also the industry as a whole.
In terms of the competitive landscape, a mix of companies are present in the minimally invasive market space. Companies with a stronger MIS focus, such as NuVasive and Globus Medical, continue to show strong growth and expand their device portfolios. In addition, many larger established companies, such as Medtronic, Zimmer Biomet, Stryker and DePuy Synthes, have developed strong portfolios in this segment. While the MIS segment shares many of the same drivers as the overall spine industry, increasing awareness and familiarity among physicians and patients are ever more important.
The major procedural drivers for MIS technology are its widely-known clinical benefits. Rather than using a large opening, MIS approaches create small ports of entry for the procedure. This method reduces muscle and tissue damage, decreases complications and extends the intraoperative time limit. As a result, recovery times can be lessened for patients while simultaneously increasing the number of procedures a physician could perform within a given amount of time, compared to the open approach.
Industry Growth is More Than Technology
While these benefits appear obvious, promoting and publicizing clinical research is important for companies. Fortunately, the innovative nature of the MIS market means that studies are often underway or being published. This includes ongoing studies on established segments of the MIS industry. In February 2017, the U.K.-based National Industry for Clinical Excellence (NICE) published a comprehensive literature review on the efficacy of the lateral approach. Reviewing over 200 articles, the study found a weighted average rate of fusion of 94%, as well as a weighted average of 60% for improvement in pain. This is a positive endorsement for MIS technologies, such as the lateral XLIF® procedure through which NuVasive established itself. The company reported that it had submitted a body of internal data for the purposes of the study.
This article was originally published on Becker’s Spine, to read more visit https://www.beckersspine.com/mis/item/40494-how-companies-are-actively-driving-growth-in-the-minimally-invasive-spinal-surgery-market.html.
For Further Information
More on the minimally invasive spinal implant market in the US can be found in a series of reports published by iData Research entitled the US Market Report Suite for Minimally Invasive Spinal Implants 2017. The full report suite on the US market for minimally invasive spinal implants includes segments for MIS interbody devices, MIS pedicle screws, spinous process fixation, facet fixation, MIS sacroiliac joint fusion, spine endoscope, and MIS spine instrumentation.
The iData report series on MIS spinal implants covers the U.S., Latin America (Brazil, Mexico, Argentina), and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxembourg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about MIS implant market data, register online or email us at [email protected] for a US Market Report Suite for Minimally Invasive Spinal Implants 2017 brochure and synopsis.